4D Molecular Therapeutics
4D Molecular Therapeutics raises $105M Series D at $800M valuation
4D Molecular Therapeutics: Series D Funding Round
4D Molecular Therapeutics has successfully raised $105M in Series D funding, reaching a valuation of $800M.
Company Overview
Targeted gene therapy vectors
Funding Details
The Series D round was led by Versant Ventures, with participation from Foresite Capital, Viking Global Investors, Fidelity.
Company Information
- Headquarters: 5858 Horton Street, Emeryville, CA 94608
- Founded: 2013
- Employees: 200+
- Category: Biotech
Investment
4D Molecular Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Versant Ventures: Verified investor in Series D
- Foresite Capital: Verified investor in Series D
- Viking Global Investors: Verified investor in Series D
- Fidelity: Verified investor in Series D
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free